[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
19
5.7kṀ38652030
36%
2030
28%
2029
21%
2028
20%
2027
16%
2026
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000People are also trading
Related questions
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
39% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a junk/fast food company use engineered additives to mitigate the effects of GLP-1 agonists (Ozempic)?
11% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
15% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
81% chance